Toxicology testing in alternative specimen matrices

Clinics in Laboratory Medicine

Volumn 32, Issue 3, 2012, Pages 467-492

  Frederick, Donald L ^a  

^a Peoria Tazewell Pathology Group   (United States)

Author keywords

Cord blood; Gastric contents; Hair; Meconium; Saliva

Indexed keywords

4 HYDROXYBUTYRIC ACID; ALCOHOL; AMPHETAMINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; CANNABIS; COCAINE; LAMOTRIGINE; NICOTINE; OPIATE DERIVATIVE;

BLOOD ANALYSIS; BLOOD SAMPLING; BREAST MILK; BREATH ANALYSIS; CHEMICAL ANALYSIS; COLOSTRUM; DRIED BLOOD SPOT TESTING; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG HAIR LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; EMERGENCY CARE; HAIR ANALYSIS; HEALTH SURVEY; HUMAN; IMMUNOASSAY; LUNG LAVAGE; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENOMICS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SALIVA ANALYSIS; STOMACH CONTENT; SWEAT TEST; TOBACCO DEPENDENCE; TOXICITY TESTING; UMBILICAL CORD BLOOD;

BODY FLUIDS; CLINICAL LABORATORY TECHNIQUES; HAIR; HUMANS; MECONIUM; SALIVA; TOXICITY TESTS;

EID: 84865582771     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2012.06.009     Document Type: Review

References (159)

1. Horning M.G., Brown L., Nowlin J., et al. Use of saliva in therapeutic drug monitoring. Clin Chem 1977, 23:157-164.
2. Langman L.J. The use of oral fluid for therapeutic drug management: clinical and forensic toxicology. Ann N Y Acad Sci 2007, 1098:145-166.
3. Siegel I.A. The role of saliva in drug monitoring. Ann N Y Acad Sci 1993, 694:86-90.
4. Aps J.K., Martens L.C. Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005, 150:119-131.
5. Farnaud S.J., Kosti O., Getting S.J., et al. Saliva: physiology and diagnostic potential in health and disease. Scientific World Journal 2010, 10:434-456.
6. Dawes C. Salivary flow patterns and the health of hard and soft oral tissues. J Am Dent Assoc 2008, 139(Suppl):18S-24S.
7. O'Neal C.L., Crouch D.J., Rollins D.E., et al. Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration. J Anal Toxicol 1999, 23:452-459.
8. Kidwell D.A., Holland J.C., Athanaselis S. Testing for drugs of abuse in saliva and sweat. J Chromatogr B Biomed Sci Appl 1998, 713:111-135.
9. Mullangi R., Agrawal S., Srinivas N.R. Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix?. Case studies and analytical perspectives. Biomed Chromatogr 2009, 23:3-25.
10. Lee H.S., Ti T.Y., Koh Y.K., et al. Paracetamol elimination in Chinese and Indians in Singapore. Eur J Clin Pharmacol 1992, 43:81-84.
11. Kopecky E.A., Jacobson S., Klein J., et al. Correlation of morphine sulfate in blood plasma and saliva in pediatric patients. Ther Drug Monit 1997, 19:530-534.
12. Wille S.M., Raes E., Lillsunde P., et al. Relationship between oral fluid and blood concentrations of drugs of abuse in drivers suspected of driving under the influence of drugs. Ther Drug Monit 2009, 31:511-519.
13. Ryan M., Grim S.A., Miles M.V., et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy 2003, 23:1550-1557.
14. Crouch D.J. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int 2005, 150:165-173.
15. Drummer O.H. Introduction and review of collection techniques and applications of drug testing of oral fluid. Ther Drug Monit 2008, 30:203-206.
16. Crouch D.J., Walsh J.M., Cangianelli L., et al. Laboratory evaluation and field application of roadside oral fluid collectors and drug testing devices. Ther Drug Monit 2008, 30:188-195.
17. Drummer O.H. Drug testing in oral fluid. Clin Biochem Rev 2006, 27:147-159.
18. Vanstechelman S., Isalberti C., Van der Linden T., et al. Analytical evaluation of four on-site oral fluid drug testing devices. J Anal Toxicol 2012, 36:136-140.
19. Dvorchik B.H., Vesell E.S. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem 1976, 22:868-878.
20. Liu H., Delgado M.R. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 1999, 36:453-470.
21. Miles M.V., Tang P.H., Glauser T.A., et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol 2003, 29:143-147.
22. Grim S.A., Ryan M., Miles M.V., et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit 2003, 2561-2566.
23. Miles M.V., Tang P.H., Ryan M.A., et al. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit 2004, 26:300-304.
24. Jones M.D., Ryan M., Miles M.V., et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit 2005, 27(5):576-579.
25. Jaber M., Schneider A.T., Goldstein S., et al. Reliability and predictive value of salivary theophylline levels. Ann Allergy 1987, 58:105-108.
26. Blanchard J., Harvey S., Morgan W.J. Relationship between serum and saliva theophylline levels in patients with cystic fibrosis. Ther Drug Monit 1992, 14:48-54.
27. Blanchard J., Harvey S., Morgan W.J. Serum/saliva correlations for theophylline in asthmatics. J Clin Pharmacol 1991, 31:565-570.
28. Henkin R.I. Comparative monitoring of oral theophylline treatment in blood serum, saliva, and nasal mucus. Ther Drug Monit 2012, 34:217-221.
29. Maudens K.E., Stove C.P., Lambert W.E. Quantitative liquid chromatographic analysis of anthracyclines in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:2471-2486.
30. Maudens K.E., Stove C.P., Cocquyt V.F., et al. Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(30):3907-3915.
31. Haeckel R., Bucklitsch I. The comparability of ethanol concentrations in peripheral blood and saliva. The phenomenon of variation in saliva to blood concentration ratios. J Clin Chem Clin Biochem 1987, 25:199-204.
32. Hoiseth G., Yttredal B., Karinen R., et al. Ethyl glucuronide concentrations in oral fluid, blood, and urine after volunteers drank 0.5 and 1.0 g/kg doses of ethanol. J Anal Toxicol 2010, 34:319-324.
33. Drummer O.H. Review: pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 2005, 150:133-142.
34. Pil K., Verstraete A. Current developments in drug testing in oral fluid. Ther Drug Monit 2008, 30:196-202.
35. Link B., Haschke M., Grignaschi N., et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol 2008, 66:473-484.
36. Link B., Haschke M., Wenk M., et al. Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. Rapid Commun Mass Spectrom 2007, 21:1531-1540.
37. Lutz U., Völkel W., Lutz R.W., et al. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 813:217-225.
38. Heltsley R., DePriest A., Black D.L., et al. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol 2011, 35:529-540.
39. Heltsley R., DePriest A., Black D.L., et al. Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens. J Anal Toxicol 2012, 36:75-80.
40. Shiran M.R., Hassanzadeh-Khayyat M., Iqbal M.Z., et al. Can saliva replace plasma for the monitoring of methadone?. Ther Drug Monit 2005, 27:580-586.
41. Moore C., Rana S., Coulter C. Determination of meperidine, tramadol and oxycodone in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 850:370-375.
42. Coulter C., Taruc M., Tuyay J., et al. Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2010, 34:64-72.
43. Coulter C., Taruc M., Tuyay J., et al. Determination of tapentadol and its metabolite N-desmethyltapentadol in urine and oral fluid using liquid chromatography with tandem mass spectral detection. J Anal Toxicol 2010, 34:458-463.
44. Lanaro R., Costa J.L., Fernandes L.C., et al. Detection of paraquat in oral fluid, plasma, and urine by capillary electrophoresis for diagnosis of acute poisoning. J Anal Toxicol 2011, 35:274-279.
45. Verstraete A., Raes E. ROSITA-2 Project final report 2006, 1-257. Ghent University Department of Clinical Biology, Microbiology and Immunity, Gent (Belgium).
46. Garnier M., Coulter C., Moore C. Selection of an immunoassay screening cutoff concentration for opioids in oral fluid. J Anal Toxicol 2011, 35:369-374.
47. Miller E.I., Norris H.R., Rollins D.E., et al. Identification and quantification of nicotine biomarkers in human oral fluid from individuals receiving low-dose transdermal nicotine: a preliminary study. J Anal Toxicol 2010, 34:357-366.
48. Scheidweiler K.B., Shakleya D.M., Huestis M.A. Simultaneous quantification of nicotine, cotinine, trans-3'-hydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2012, 413:978-984.
49. Scheidweiler K.B., Marrone G.F., Shakleya D.M., et al. Oral fluid nicotine markers to assess smoking status and recency of use. Ther Drug Monit 2011, 33:609-618.
50. Paul B.D., Smith M.L. Cyanide and thiocyanate in human saliva by gas chromatography-mass spectrometry. J Anal Toxicol 2006, 30:511-515.
51. Lee D., Schwope D.M., Milman G., et al. Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem 2012, 58:748-756.
52. Coulter C.M., Garnier M., Moore C. Synthetic cannabinoids in oral fluid. J Anal Toxicol 2011, 35:424-430.
53. Blencowe T., Pehrsson A., Lillsunde P., et al. An analytical evaluation of eight on-site oral fluid drug screening devices using laboratory confirmation results from oral fluid. Forensic Sci Int 2011, 208:173-179.
54. Gronholm M., Lillsunde P. A comparison between on-site immunoassay drug-testing devices and laboratory results. Forensic Sci Int 2001, 121:37-46.
55. Moore C., Coulter C., Crompton K., et al. Determination of benzodiazepines in oral fluid using LC-MS-MS. J Anal Toxicol 2007, 31:596-600.
56. Smink B.E., Mathijssen M.P., Lusthof K.J., et al. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine-like substances using immunoassay and LC-MS(-MS). J Anal Toxicol 2006, 30:478-485.
57. Moore C., Coulter C., Crompton K. Achieving proposed federal concentrations using reduced specimen volume for the extraction of amphetamines from oral fluid. J Anal Toxicol 2007, 31:442-446.
58. De Paoli G., Bell S. A rapid GC-MS determination of gamma-hydroxybutyrate in saliva. J Anal Toxicol 2008, 32:298-302.
59. Abanades S., Farré M., Segura M., et al. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther Drug Monit 2007, 29:64-70.
60. Juberg D.R., Kleiman C.F., Kwon S.C. Position paper of the American Council on Science and Health: lead and human health. Ecotoxicol Environ Saf 1997, 38:162-180.
61. Keller D.A., Juberg D.R., Catlin N., et al. Identification and characterization of adverse effects in 21st century toxicology. Toxicol Sci 2012, 126:291-297.
62. Pirkle J.L., Needham L.L., Sexton K. Improving exposure assessment by monitoring human tissues for toxic chemicals. J Expo Anal Environ Epidemiol 1995, 5:405-424.
63. Gonzalez M., Banderas J.A., Baez A., et al. Salivary lead and cadmium in a young population residing in Mexico City. Toxicol Lett 1997, 93:55-64.
64. Timchalk C., Lin Y., Weitz K.K., et al. Disposition of lead (Pb) in saliva and blood of Sprague-Dawley rats following a single or repeated oral exposure to Pb-acetate. Toxicology 2006, 222:86-94.
65. Yantasee W., Timchalk C., Weitz K.K., et al. Optimization of a portable microanalytical system to reduce electrode fouling from proteins associated with biomonitoring of lead (Pb) in saliva. Talanta 2005, 67:617-624.
66. Yantasee W., Timchalk C., Lin Y. Microanalyzer for biomonitoring lead (Pb) in blood and urine. Anal Bioanal Chem 2007, 387:335-341.
67. Gil F., Hernández A.F., Márquez C., et al. Biomonitorization of cadmium, chromium, manganese, nickel and lead in whole blood, urine, axillary hair and saliva in an occupationally exposed population. Sci Total Environ 2011, 409:1172-1180.
68. Lew K., Acker J.P., Gabos S., et al. Biomonitoring of arsenic in urine and saliva of children playing on playgrounds constructed from chromated copper arsenate-treated wood. Environ Sci Technol 2010, 44:3986-3991.
69. Yuan C., Lu X., Oro N., et al. Arsenic speciation analysis in human saliva. Clin Chem 2008, 54:163-171.
70. Olmedo P., Pla A., Hernández A.F., et al. Validation of a method to quantify chromium, cadmium, manganese, nickel and lead in human whole blood, urine, saliva and hair samples by electrothermal atomic absorption spectrometry. Anal Chim Acta 2010, 659:60-67.
71. Sutton M., Burastero S.R. Beryllium chemical speciation in elemental human biological fluids. Chem Res Toxicol 2003, 16:1145-1154.
72. Schutte-Borkovec K., Heppel C.W., Heling A.K., et al. Analysis of myosmine, cotinine and nicotine in human toenail, plasma and saliva. Biomarkers 2009, 14:278-284.
73. Oiestad E.L., Johansen U., Christophersen A.S. Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. Clin Chem 2007, 53:300-309.
74. Lillsunde P. Analytical techniques for drug detection in oral fluid. Ther Drug Monit 2008, 30:181-187.
75. Wille S.M., Samyn N., Ramírez-Fernández Mdel M., et al. Evaluation of on-site oral fluid screening using Drugwipe-5(+), RapidSTAT and Drug Test 5000 for the detection of drugs of abuse in drivers. Forensic Sci Int 2010, 198:2-6.
76. Jaedicke K.M., Taylor J.J., Preshaw P.M. Validation and quality control of ELISAs for the use with human saliva samples. J Immunol Methods 2012, 377:62-65.
77. Huestis M.A., Verstraete A., Kwong T.C., et al. Oral fluid testing: promises and pitfalls. Clin Chem 2011, 57:805-810.
78. Schwope D.M., Milman G., Huestis M.A. Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid. Clin Chem 2010, 56:1007-1014.
79. Wylie F.M., Torrance H., Anderson R.A., et al. Drugs in oral fluid Part I. Validation of an analytical procedure for licit and illicit drugs in oral fluid. Forensic Sci Int 2005, 150:191-198.
80. Lloyd D.K. Capillary electrophoresis analysis of biofluids with a focus on less commonly analyzed matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 866:154-166.
81. Fritch D., Blum K., Nonnemacher S., et al. Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2009, 33:569-577.
82. Tuyay J., Coulter C., Rodrigues W., et al. Disposition of opioids in oral fluid: Importance of chromatography and mass spectral transitions in LC-MS/MS. Drug Test Anal 2012, 4(6):395-401.
83. Dams R., Murphy C.M., Choo R.E., et al. LC-atmospheric pressure chemical ionization-MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. Anal Chem 2003, 75:798-804.
84. Smink B.E., Egberts A.C., Lusthof K.J., et al. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs 2010, 24:639-653.
85. Cone E.J., Huestis M.A. Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci 2007, 1098:51-103.
86. Lee D., Schwope D.M., Milman G., et al. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem 2011, 57:1127-1136.
87. Moore C., Coulter C., Uges D., et al. Cannabinoids in oral fluid following passive exposure to marijuana smoke. Forensic Sci Int 2011, 212:227-230.
88. Toennes S.W., Ramaekers J.G., Theunissen E.L., et al. Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol 2010, 34:216-221.
89. Kato K., Hillsgrove M., Weinhold L., et al. Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol 1993, 17:338-341.
90. Hindmarsh J.T. Caveats in hair analysis in chronic arsenic poisoning. Clin Biochem 2002, 35:1-11.
91. Egeland G.M., Ponce R., Knecht R., et al. Trace metals in ancient hair from the Karluk Archaeological Site, Kodiak, Alaska. Int J Circumpolar Health 1999, 58:52-56.
92. Baumgartner A.M., Jones P.F., Baumgartner W.A., et al. Radioimmunoassay of hair for determining opiate-abuse histories. J Nucl Med 1979, 20:748-752.
93. Kintz P., Villain M., Cirimele V. Hair analysis for drug detection. Ther Drug Monit 2006, 28:442-446.
94. Barroso M., Gallardo E., Vieira D.N., et al. Hair: a complementary source of bioanalytical information in forensic toxicology. Bioanalysis 2011, 3:67-79.
95. Auwarter V., Wohlfarth A., Traber J., et al. Hair analysis for Delta9-tetrahydrocannabinolic acid A-new insights into the mechanism of drug incorporation of cannabinoids into hair. Forensic Sci Int 2010, 196:10-13.
96. Cone E.J., Preston K.L. Toxicologic aspects of heroin substitution treatment. Ther Drug Monit 2002, 24:193-198.
97. Drug testing in hair 1996, CRC Press, Boca Raton (FL). P. Kintz (Ed.).
98. Driskell R.R., Clavel C., Rendl M., et al. Hair follicle dermal papilla cells at a glance. J Cell Sci 2011, 124:1179-1182.
99. Shimomura Y., Christiano A.M. Biology and genetics of hair. Annu Rev Genomics Hum Genet 2010, 11:109-132.
100. Han E., Choi H., Lee S., et al. A comparative study on the concentrations of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in head and pubic hair. Forensic Sci Int 2011, 212:238-241.
101. Han E., Choi H., Lee S. A study on the concentrations of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in hair root and whole hair. Forensic Sci Int 2011, 210:201-205.
102. Sramek J.J., Baumgartner W.A., Tallos J.A., et al. Hair analysis for detection of phencyclidine in newly admitted psychiatric patients. Am J Psychiatry 1985, 142:950-953.
103. Kulaga V., Shor S., Koren G. Correlation between drugs of abuse and alcohol by hair analysis: parents at risk for having children with fetal alcohol spectrum disorder. Alcohol 2010, 44:615-621.
104. Kulaga V., Pragst F., Fulga N., et al. Hair analysis of fatty acid ethyl esters in the detection of excessive drinking in the context of fetal alcohol spectrum disorders. Ther Drug Monit 2009, 31:261-266.
105. Pragst F., Rothe M., Moench B., et al. Combined use of fatty acid ethyl esters and ethyl glucuronide in hair for diagnosis of alcohol abuse: interpretation and advantages. Forensic Sci Int 2010, 196:101-110.
106. Pragst F., Yegles M. Determination of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in hair: a promising way for retrospective detection of alcohol abuse during pregnancy?. Ther Drug Monit 2008, 30:255-263.
107. Kulaga V., Gareri J., Fulga N., et al. Agreement between the fatty acid ethyl ester hair test for alcohol and social workers' reports. Ther Drug Monit 2010, 32:294-299.
108. Florescu A., Ferrence R., Einarson T., et al. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit 2009, 31:14-30.
109. Florescu A., Ferrence R., Einarson T.R., et al. Reference values for hair cotinine as a biomarker of active and passive smoking in women of reproductive age, pregnant women, children, and neonates: systematic review and meta-analysis. Ther Drug Monit 2007, 29:437-446.
110. Klein J., Koren G. Hair analysis-a biological marker for passive smoking in pregnancy and childhood. Hum Exp Toxicol 1999, 18:279-282.
111. Cace I.B., Milardovic A., Prpic I., et al. Relationship between the prenatal exposure to low-level of mercury and the size of a newborn's cerebellum. Med Hypotheses 2011, 76:514-516.
112. Garcia-Bournissen F., Rokach B., Karaskov T., et al. Cocaine detection in maternal and neonatal hair: implications to fetal toxicology. Ther Drug Monit 2007, 29:71-76.
113. Williams J., Lawthom C., Dunstan F.D., et al. Variability of antiepileptic medication taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy. J Neurol Neurosurg Psychiatry 2006, 77:481-484.
114. Klys M., Szydlowski L., Rojek S. Role of toxicological determinations of amphetamines and cannabinoids in hair of adolescent patients in cardiologic diagnostic management. Cardiol Young 2012, 22:8-12.
115. Thomson S., Koren G., Van Steen V., et al. Testosterone concentrations in hair of hypogonadal men with and without testosterone replacement therapy. Ther Drug Monit 2009, 31:779-782.
116. Gow R., Koren G., Rieder M., Van Uum S. Hair cortisol content in patients with adrenal insufficiency on hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 2011, 74:687-693.
117. Gow R., Thomson S., Rieder M., et al. An assessment of cortisol analysis in hair and its clinical applications. Forensic Sci Int 2010, 196:32-37.
118. Russell E., Koren G., Rieder M., et al. Hair cortisol as a biological marker of chronic stress: Current status, future directions and unanswered questions. Psychoneuroendocrinology 2012, 37:589-601.
119. Sauve B., Koren G., Walsh G., et al. Measurement of cortisol in human hair as a biomarker of systemic exposure. Clin Invest Med 2007, 30:E183-E191.
120. Cirimele V., Kintz P. Identification of benzodiazepines in human hair: a review. Benzodiazepines and GHB: detection and pharmacology 2001, 77-92. Humana Press, Totowa (NJ). S.J. Salamone (Ed.).
121. de la Torre R., Civit E., Svaizer F., et al. High throughput analysis of drugs of abuse in hair by combining purposely designed sample extraction compatible with immunometric methods used for drug testing in urine. Forensic Sci Int 2010, 196:18-21.
122. Baumgartner M.R., Guglielmello R., Fanger M., et al. Analysis of drugs of abuse in hair: evaluation of the immunochemical method VMA-T vs. LC-MS/MS or GC-MS. Forensic Sci Int 2012, 215:56-59.
123. Zimmermann C.M., Jackson G.P. Gas chromatography tandem mass spectrometry for biomarkers of alcohol abuse in human hair. Ther Drug Monit 2010, 32:216-223.
124. Musshoff F., Kirschbaum K.M., Graumann K., et al. Evaluation of two immunoassay procedures for drug testing in hair samples. Forensic Sci Int 2012, 215:60-63.
125. Dominguez-Romero J.C., Garcia-Reyes J.F., Molina-Diaz A. Screening and quantitation of multiclass drugs of abuse and pharmaceuticals in hair by fast liquid chromatography electrospray time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:2034-2042.
126. Kim J.Y., Cheong J.C., Lee J.I., et al. Improved gas chromatography-negative ion chemical ionization tandem mass spectrometric method for determination of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in hair using mechanical pulverization and bead-assisted liquid-liquid extraction. Forensic Sci Int 2011, 206:e99-e102.
127. Henderson G.L., Harkey M.R., Zhou C., et al. Incorporation of isotopically labeled cocaine and metabolites into human hair: 1. Dose-response relationships. J Anal Toxicol 1996, 20:1-12.
128. LeBeau M.A., Montgomery M.A., Brewer J.D. The role of variations in growth rate and sample collection on interpreting results of segmental analyses of hair. Forensic Sci Int 2011, 210:110-116.
129. LeBeau M.A. Guidance for improved detection of drugs used to facilitate crimes. Ther Drug Monit 2008, 30:229-233.
130. Joseph R.E., Su T.P., Cone E.J. In vitro binding studies of drugs to hair: influence of melanin and lipids on cocaine binding to Caucasoid and Africoid hair. J Anal Toxicol 1996, 20:338-344.
131. Henderson G.L., Harkey M.R., Zhou C., et al. Incorporation of isotopically labeled cocaine into human hair: race as a factor. J Anal Toxicol 1998, 22:156-165.
132. Han E., Park Y., Kim E., et al. The dependence of the incorporation of methamphetamine into rat hair on dose, frequency of administration and hair pigmentation. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2845-2851.
133. Falcon M., Pichini S., Joya J., et al. Maternal hair testing for the assessment of fetal exposure to drug of abuse during early pregnancy: comparison with testing in placental and fetal remains. Forensic Sci Int 2011, 218:92-96.
134. Joya X., Gomez-Culebras M., Callejón A., et al. Cocaine use during pregnancy assessed by hair analysis in a Canary Islands cohort. BMC Pregnancy Childbirth 2012, 12:2.
135. Pichini S., De Luca R., Pellegrini M., et al. Hair and urine testing to assess drugs of abuse consumption in couples undergoing assisted reproductive technology (ART). Forensic Sci Int 2012, 218:57-61.
136. Musshoff F., Lachenmeier K., Trafkowski J., et al. Determination of opioid analgesics in hair samples using liquid chromatography/tandem mass spectrometry and application to patients under palliative care. Ther Drug Monit 2007, 29:655-661.
137. Kintz P., Villain M., Cirimele V. Chemical abuse in the elderly: evidence from hair analysis. Ther Drug Monit 2008, 30:207-211.
138. Lozano J., García-Algar O., Vall O., et al. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit 2007, 29:711-734.
139. Montgomery D., Plate C., Alder S.C., et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol 2006, 26:11-14.
140. Gray T.R., Kelly T., LaGasse L.L., et al. New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates. Clin Chem 2010, 56:856-860.
141. Gray T.R., Kelly T., LaGasse L.L., et al. Novel biomarkers of prenatal methamphetamine exposure in human meconium. Ther Drug Monit 2009, 31:70-75.
142. Hutson J.R., Rao C., Fulga N., et al. An improved method for rapidly quantifying fatty acid ethyl esters in meconium suitable for prenatal alcohol screening. Alcohol 2011, 45:193-199.
143. Gareri J., Lynn H., Handley M., et al. Prevalence of fetal ethanol exposure in a regional population-based sample by meconium analysis of fatty acid ethyl esters. Ther Drug Monit 2008, 30:239-245.
144. Casadio Y.S., Williams T.M., Lai C.T., et al. Evaluation of a mid-infrared analyzer for the determination of the macronutrient composition of human milk. J Hum Lact 2010, 26:376-383.
145. Barnes A.J., Brunet B.R., Choo R.E., et al. Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration. Ther Drug Monit 2010, 32:497-503.
146. Brunet B.R., Barnes A.J., Choo R.E., et al. Monitoring pregnant women's illicit opiate and cocaine use with sweat testing. Ther Drug Monit 2010, 32:40-49.
147. Appenzeller B.M., Schummer C., Rodrigues S.B., et al. Determination of the volume of sweat accumulated in a sweat-patch using sodium and potassium as internal reference. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 852:333-337.
148. Schummer C., Appenzeller B.M., Wennig R. Quantitative determination of ethyl glucuronide in sweat. Ther Drug Monit 2008, 30:536-539.
149. Marchei E., Papaseit E., Garcia-Algar O.Q., et al. Determination of atomoxetine and its metabolites in conventional and non-conventional biological matrices by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2012, 60:26-31.
150. Concheiro M., Jones H.E., Johnson R.E., et al. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit 2011, 33:619-626.
151. Concheiro M., Shakleya D.M., Huestis M.A. Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 2011, 400:69-78.
152. Marchei E., Farré M., Pardo R., et al. Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study. Ther Drug Monit 2010, 32:508-511.
153. Kintz P., Cirimele V., Ludes B. Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 2000, 24:557-561.
154. Beck O., Leine K., Palmskog G., et al. Amphetamines detected in exhaled breath from drug addicts: a new possible method for drugs-of-abuse testing. J Anal Toxicol 2010, 34:233-237.
155. Day R.O., McLachlan A.J., Graham G.G., et al. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999, 36:191-210.
156. Li Y., Henion J., Abbott R., et al. The use of a membrane filtration device to form dried plasma spots for the quantitative determination of guanfacine in whole blood. Rapid Commun Mass Spectrom 2012, 26:1208-1212.
157. Stove C.P., Ingels A.S., De Kesel P.M., et al. Dried blood spots in toxicology: from the cradle to the grave?. Crit Rev Toxicol 2012, 42:230-243.
158. Pandya H.C., Spooner N., Mulla H. Dried blood spots, pharmacokinetic studies and better medicines for children. Bioanalysis 2011, 3:779-786.
159. Patel P., Mulla H., Tanna S., et al. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child 2010, 95:484-487.